Groupe PTC Therapeutics, Inc.

PTC Therapeutics International Ltd. is an Irish biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare diseases with high unmet medical needs. The company is based in DU. The company addresses the root causes of serious genetic, metabolic, and neurological conditions through approaches such as RNA splicing modulation and targeting oxidative stress and inflammation pathways, particularly in central nervous system disorders. Its therapeutic portfolio and pipeline include treatments for rare diseases such as phenylketonuria (PKU), aromatic l-amino acid decarboxylase (AADC) deficiency, Duchenne muscular dystrophy (DMD), hereditary transthyretin amyloidosis (hATTR), familial partial lipodystrophy (FPL), spinal muscular atrophy (SMA), and Friedreich’s ataxia. PTC collaborates with partners to bring treatments to market and supports patients, caregivers, and healthcare providers through educational programs and personalized assistance. The company conducts clinical trials and investigator-initiated studies, maintains dedicated patient engagement teams, and emphasizes corporate responsibility, compliance, and transparency with investors.